Selective Serotonin Reuptake Inhibitors and Associated Bleeding Risks: A Narrative and Clinical Review
Major Depressive Disorder (MDD) is a major cause of disability worldwide and is associated with serious lasting impairment. A leading hypothesis of the pathophysiology of MDD is the monoamine deficiency hypothesis which suggests that depression is caused by depletion of serotonin, norepinephrine, or dopamine in the central nervous system. Serotonin is the most widely studied neurotransmitter in the pathophysiology of depression, with studies showing that reduced central serotonin synthesis leads to depressive symptoms in individuals at risk for depression. Selective Serotonin Reuptake Inhibitors (SSRI) inhibit serotonin reuptake and subsequently increase the amount of serotonin available in synapses. Common side effects of SSRIs include increased suicidality of patients under the age of 25, sexual dysfunction, anxiety, dizziness, weight gain, gastrointestinal distress, and headache. Other side effects include prolonging the QT interval, coagulopathy, and the risk of serotonin syndrome, as well as SSRI discontinuation syndrome. Sites of increased bleeding related to SSRI use have been reported to occur in the upper gastrointestinal tract, as well as intracranially. Based on the current literature, three studies have found that SSRIs are not associated with increased bleeding and/or increased perioperative risk, while others have demonstrated that SSRIs are associated with an increased risk in perioperative use. The inhibition of serotonin reuptake can affect platelet aggregation since platelets also express the serotonin transporter. SSRIs can result in decreased storage of serotonin in platelet dense granules. Increased serotonin can also increase gastric acid secretion, which increases the risk for ulceration. SSRIs in combination with NSAIDs also show a significantly increased risk of upper GI bleeding. Some studies show an increased bleeding risk from 30% to 70% when taking a combination of vitamin K antagonists and SSRIs in hospitalized patients. Related to the high prevalence of conditions that are treated with SSRIs, the bleeding risk associated with this class of medication merits further study.
1. Uher R, Payne JL, Pavlova B, Perlis RH. Major depressive disorder in DSM-5: Implications for clinical practice and research of changes from DSM-IV. Depress Anxiety. 2014;31(6):459-471. doi:10.1002/da.22217
2. Carrasco JL, Sandner C. Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: An overview. Int J Clin Pract. 2005;59(12):1428-1434. doi:10.1111/j.1368-5031.2005.00681.x
3. Joshi A. Selective Serotonin Re-uptake Inhibitors: An overview. Psychiatr Danub. 2018;30(Suppl 7):605-609.
4. Negrão AB, Gold PW. Major Depressive Disorder. In: Encyclopedia of Stress. 2nd ed. Academic Press; 2007:640-645. https://doi.org/10.1016/b978-012373947-6.00245-2
5. Rush AJ. The varied clinical presentations of major depressive disorder. Journal of Clinical Psychiatry. 2007;68:4-10.
6. Hasin DS, Sarvet AL, Meyers JL, et al. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiatry. 2018;75(4):336. doi:10.1001/jamapsychiatry.2017.4602
7. Hasler G. Pathophysiology of depression: Do we have any solid evidence of interest to clinicians? World Psychiatry. 2010;9(3):155-161. doi:10.1002/j.2075-5545.2010.tb00298.x
8. Latendresse G, Elmore C, Deneris A. Selective Serotonin Reuptake Inhibitors as First-Line Antidepressant Therapy for Perinatal Depression. Journal of Midwifery & Women’s Health. 2017;62(3):317-328. doi:10.1111/jmwh.12607
9. Tan JY, Levin GM. Citalopram in the treatment of depression and other potential uses in psychiatry. Pharmacotherapy. 1999;19(6):675-689. doi:10.1592/phco.19.9.675.31538
10. Chung S. Does the use of SSRIs reduce medical care utilization and expenditures? - PubMed. J Ment Health Policy Econ. 2005;8(3):119-129.
11. Barakat A, Hamdy MM, Elbadr MM. Uses of fluoxetine in nociceptive pain management: A literature overview. European Journal of Pharmacology. 2018;829:12-25. doi:10.1016/j.ejphar.2018.03.042
12. Strawn JR, Mills JA, Croarkin PE. Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy. J Child Adolesc Psychopharmacol. 2019;29(4):250-255. doi:10.1089/cap.2018.0145
13. Taylor C, Fricker AD, Devi LA, Gomes I. Mechanisms of action of antidepressants: From neurotransmitter systems to signaling pathways. Cellular Signalling. 2005;17(5):549-557. doi:10.1016/j.cellsig.2004.12.007
14. Chu A, Wadhwa R. Selective Serotonin Reuptake Inhibitors. In: StatPearls. StatPearls Publishing; 2020.
15. DeVane CL. Pharmacokinetics of the selective serotonin reuptake inhibitors. J Clin Psychiatry. 1992;53(2 SUPPL.):13-20.
16. van Harten J. Clinical Pharmacokinetics of Selective Serotonin Reuptake Inhibitors. Clinical Pharmacokinetics. 1993;24(3):203-220. doi:10.2165/00003188-199324030-00003
17. Bismuth-Evenzal Y, Gonopolsky Y, Gurwitz D, Iancu I, Weizman A, Rehavi M. Decreased serotonin content and reduced agonist-induced aggregation in platelets of patients chronically medicated with SSRI drugs. Journal of Affective Disorders. 2012;136(1-2):99-103. doi:10.1016/j.jad.2011.08.013
18. Halperin D, Reber G. Influence of antidepressants on hemostasis. Dialogues in Clinical Neuroscience. 2007;9(1):47-59. doi:10.31887/dcns.2007.9.1/dhalperin
19. Mammadova-Bach E, Mauler M, Braun A, Duerschmied D. Immuno-Thrombotic Effects of Platelet Serotonin. Serotonin - A Chemical Messenger Between All Types of Living Cells. Published online July 26, 2017. doi:10.5772/intechopen.69349
20. Andrade C, Sharma E. Serotonin Reuptake Inhibitors and Risk of Abnormal Bleeding. Psychiatr Clin North Am. 2016;39(3):413-426. doi:10.1016/j.psc.2016.04.010
21. Yuet WC, Derasari D, Sivoravong J, Mason D, Jann M. Selective serotonin reuptake inhibitor use and risk of gastrointestinal and intracranial bleeding. J Am Osteopath Assoc. 2019;119(2):102-111. doi:10.7556/jaoa.2019.016
22. Bixby AL, VandenBerg A, Bostwick JR. Clinical Management of Bleeding Risk With Antidepressants. Ann Pharmacother. 2019;53(2):186-194. doi:10.1177/1060028018794005
23. Jiang HY, Chen HZ, Hu XJ, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: A systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2015;13(1):42-50.e3. doi:10.1016/j.cgh.2014.06.021
24. Quinn GR, Hellkamp AS, Hankey GJ, et al. Selective serotonin reuptake inhibitors and bleeding risk in anticoagulated patients with atrial fibrillation: An analysis from the ROCKET AF trial. J Am Heart Assoc. 2018;7(15):1-9. doi:10.1161/jaha.118.008755
25. Anglin R, Yuan Y, Moayyedi P, Tse F, Armstrong D, Leontiadis GI. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: A systematic review and meta-analysis. Am J Gastroenterol. 2014;109(6):811-819. doi:10.1038/ajg.2014.82
26. Perrotta C, Giordano F, Colombo A, et al. Postpartum Bleeding in Pregnant Women Receiving SSRIs/SNRIs: New Insights From a Descriptive Observational Study and an Analysis of Data from the FAERS Database. Clin Ther. 2019;41(9):1755-1766. doi:10.1016/j.clinthera.2019.06.008
27. Basile FV, Basile AR, Basile VV. Use of selective serotonin reuptake inhibitors antidepressants and bleeding risk in breast cosmetic surgery. Aesth Plast Surg. 2013;37(3):561-566. doi:10.1007/s00266-013-0111-7
28. Chang Chien GC, McCormick Z, Araujo M, Candido KD. The potential contributing effect of ketorolac and fluoxetine to a spinal epidural hematoma following a cervical interlaminar epidural steroid injection: A case report and narrative review. Pain Phys. 2014;17(3):E385-E395. doi:10.36076/ppj.2014/17/e385
29. Lagerkranser M. Neuraxial blocks and spinal haematoma: Review of 166 case reports published 1994–2015. Part 1: Demographics and risk-factors. Scandinavian Journal of Pain. 2017;15(1):118-129. doi:10.1016/j.sjpain.2016.11.008
30. Luzzi C, Salata K, Djaiani C, et al. Selective serotonin re-uptake inhibitors: Risk of blood product transfusion and inotrope requirements in patients undergoing cardiac surgery. J Thorac Dis. 2019;11(8):3496-3504.
31. Smith MM, Smith BB, Lahr BD, et al. Selective serotonin reuptake inhibitors and serotonin–norepinephrine reuptake inhibitors are not associated with bleeding or transfusion in cardiac surgical patients. Anesth Analg. 2018;126(6):1859-1866. doi:10.1213/ane.00000000002668
32. Shepherd SJ, Fiandeiro C, Sanders RD. Selective serotonin reuptake inhibitors: Depressing perioperative outcomes? British Journal of Anaesthesia. 2015;115(1):5-7. doi:10.1093/bja/aev065
33. Auerbach AD, Vittinghoff E, Maselli J, Pekow PS, Young JQ, Lindenauer PK. Perioperative use of selective serotonin reuptake inhibitors and risks for adverse outcomes of surgery. JAMA Intern Med. 2013;173(12):1075-1081. doi:10.1001/jamainternmed.2013.714
34. Van Haelst IMM, Egberts TCG, Doodeman HJ, et al. Use of serotonergic antidepressants and bleeding risk in orthopedic patients. Anesthesiology. 2010;112(3):631-636. doi:10.1097/aln.0b013e3181cf8fdf
35. Antithrombotic Guidelines. Accessed January 2, 2021. https://asipp.org/antithrombotic-guidelines/